Erika Hamilton: Happy to share publication on updated monarchE data with adjuvant abemaciclib

Erika Hamilton , Chair of Executive Committee Breast and Breast Program lead at Sarah Cannon Research Institute, shared on LinkedIn:

“Happy to share publication on updated monarchE data with adjuvant abemaciclib. With 5 year follow-up, we see continued separation of curves after 2 year abema treatment period.

DFS benefit at 5 years is now 7.6% favoring abema.

Although OS not significant at this follow-up, control arm has double the amount of patients now living with metastatic breast cancer.

Encouraging to know that through clinical trial participation, so many women accessed this therapy years ahead of approval.“

Read Further.
Source: Erika Hamilton/LinkedIn